Serina Therapeutics Stock Price, News & Analysis

Serina Therapeutics (NYSE: SER) announces that its strategic partner and largest shareholder, Juvenescence Ltd., has secured $76 million in the first tranche of its targeted $150 million Series B financing round. Additionally, Juvenescence has formed a strategic partnership with M42, a tech-enabled health company based in Abu Dhabi. The partnership includes plans to establish a drug development hub in Abu Dhabi, combining AI-enabled drug discovery with advanced data and clinical infrastructure. Serina Therapeutics, which is developing the POZ Platform™ drug optimization technology, views this development as beneficial due to Juvenescence's role in providing strategic guidance and capital support. The collaboration between Juvenescence and M42 aims to accelerate the development of therapies targeting age-related diseases and extending healthspan.

Serina Therapeutics (NYSE: SER) announces that its strategic partner and largest shareholder, Juvenescence Ltd., has secured $150 million in Series B funding led by M42, a tech-enabled health company from Abu Dhabi. The partnership includes plans to establish a drug development hub in Abu Dhabi, combining AI-enabled drug discovery with advanced data and clinical infrastructure. Juvenescence's investment will support the development of innovative therapies targeting age-related diseases and extending healthspan. Serina Therapeutics, which is developing its POZ Platform drug optimization technology, benefits from Juvenescence's strategic guidance and capital support in advancing their clinical programs.

Serina Therapeutics (NYSE: SER) has announced that CEO Steven A. Ledger will present at an upcoming Tribe Public Webinar titled 'Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?' scheduled for June 11, 2025, at 8:30 AM PT/11:30 AM ET. The presentation comes at a significant time as the biotech sector enters its fifth year of a bear market, with approximately 25% of 700-800 publicly traded US biotech companies showing negative enterprise values. Serina, a clinical-stage biotech company, is developing its proprietary POZ Platform for drug optimization. The event will be hosted by Tribe Public's Managing Member John F. Heerdink, Jr., and interested participants can register for free at Smartest-Bet.TribePublic.com.

Serina Therapeutics (NYSE: SER) has appointed Dr. Stephen Brannan to its Board of Directors. Dr. Brannan brings over 30 years of experience in neuroscience and neuropsychiatry drug development. He most recently served as Chief Medical Officer at Karuna Therapeutics, where he led the clinical development of KarXT, the first new schizophrenia treatment mechanism in over 30 years, which contributed to Karuna's $14 billion acquisition by Bristol Myers Squibb in 2024.

Dr. Brannan's extensive experience includes senior leadership roles at Takeda, Novartis, Cyberonics, and Eli Lilly, where he directed clinical programs in various CNS conditions. He will support Serina's strategic development of long-acting CNS therapeutics using their proprietary POZ Platform™ technology. The company also announced the departure of Remy Gross from its Board, who will continue supporting the team in a consulting role.

Serina Therapeutics (NYSE: SER), a clinical-stage biotech company developing SER-252 for advanced Parkinson's disease, has granted stock options to two new non-executive employees. The grants, totaling 15,000 shares of common stock, were made on March 20, 2025, with an exercise price matching the closing stock price on that date.

The Option Grants, approved by Serina's Compensation Committee under the 2024 Inducement Equity Plan, will vest over four years: 25% after the first year and the remaining 75% in three equal annual installments, subject to continued employment. These grants were made as employment inducements in compliance with NYSE American's Company Guide Section 711(a).

Serina's proprietary POZ Platform™ technology enables drug optimization for their lead candidate.

Serina Therapeutics (NYSE: SER) reported Q1 2025 financial results and business updates. The company secured $15 million in equity financing, including $10M from JuvVentures and $5M from board directors and investors. Key highlights include preparations for Phase 1b trial of SER-252 for advanced Parkinson's disease, scheduled for Q4 2025. The company reported a net loss of $4.8 million ($0.49 per share) compared to $15.0 million loss in Q1 2024. Operating expenses increased to $5.9M from $2.3M year-over-year. Cash position stands at $4.3M as of March 31, 2025, with runway through Q3 2025. The company also appointed two new board members and presented promising data on their POZ-lipid technology showing no immune response in contrast to PEG-lipid standards.

Serina Therapeutics, a clinical-stage biotech company listed on NYSE American under ticker SER, has announced its participation in the upcoming JonesResearch Virtual CNS Day. The company, known for developing the proprietary POZ Platform™ drug optimization technology, will be represented by CEO Steve Ledger in a fireside chat presentation.

The virtual event is scheduled for April 29, 2025, at 12:00 p.m. EDT. Registered attendees can access the live webcast through a provided Zoom link. For those unable to attend the live session, an archived replay will remain available on-demand for 90 days after the event.

Serina Therapeutics (NYSE: SER) announced that their Chief Development Officer, Dr. Randall Moreadith, will present groundbreaking data at the 4th LNP Formulation & Process Development Summit 2025 in Boston. The presentation, titled 'The PEG Dilemma – A Solution,' will take place on April 15, 2025, at 9:30 AM ET.

The presentation focuses on the company's innovative POZ-lipid technology, developed as an immune-silent alternative to PEG-lipids in mRNA vaccines and therapeutics. Key research findings show that Serina's POZ-lipid component in lipid nanoparticles (LNPs) demonstrated no IgM or IgG antibody response in rat studies with repeat dosing, unlike traditional PEG-lipid standards which triggered strong antibody responses.

This breakthrough is particularly significant as anti-PEG antibodies have been linked to anaphylaxis and serious adverse events in patients receiving PEGylated mRNA vaccines, including those from Pfizer and Moderna. The immune-silent nature of POZ-lipid technology could potentially revolutionize the development of safer LNP formulations for gene therapy and RNA-based medicines.

Serina Therapeutics (NYSE: SER) has secured $5 million in strategic funding to advance its lead clinical candidate SER-252 for Advanced Parkinson's disease. The financing involves issuing 965,250 shares of convertible preferred stock at $5.18 per share.

The funds will support the development of SER-252 (POZ-apomorphine), which utilizes Serina's proprietary POZ Platform™ drug optimization technology. The company aims to initiate a Phase 1 clinical trial in the fourth quarter of 2025. The therapeutic approach focuses on achieving continuous dopaminergic stimulation for potential clinical benefits in advanced Parkinson's disease patients.